Hiflo

Quick links to important sections

Hiflo

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hiflo

Hiflo: A Quick Overview of the Medicine

Property Description
Active Ingredient Ambroxol Hydrochloride
Form Oral Solution
Pharmacological Class Mucolytic Agent
Common Use Respiratory Support (Thick Mucus)
Origin Synthetic Compound

Hiflo is a synthetic, pharmaceutical-grade solution administered via the oral route, designed to support the management of certain respiratory conditions. This medicine contains the active pharmaceutical ingredient Ambroxol Hydrochloride, a compound manufactured synthetically to ensure consistent potency and purity. As an oral solution, Hiflo is often positioned as an easy-to-take formula particularly suitable for individuals who may have difficulty swallowing solid medications.


What is the Composition and Pharmacological Class of Hiflo?

Hiflo’s primary function is delivered by its single active ingredient, Ambroxol Hydrochloride. The drug is classified as a mucolytic agent. As a mucolytic, its principle involves altering the physical properties of mucus to facilitate its clearance from the airways.

This mechanism is recognized for its supportive role in conditions where thick respiratory secretions complicate breathing. Ambroxol Hydrochloride assists in improving the flow and clearance of respiratory secretions, which is a recognized function in respiratory care.


What is Hiflo Used For? (General Therapeutic Purpose)

The general therapeutic purpose of Hiflo is the supportive treatment of conditions characterized by excessive or thick mucus secretion in the airways. It is intended to assist in promoting respiratory clearance. This class of medicine is intended to thin and loosen mucus in the lungs. Therefore, Hiflo is used to relieve the discomfort associated with a congested chest by providing the necessary support for the body to expel the secretions more easily.

What side effects are possible with Hiflo?

Possible side effects and safety information

Official government regulatory documents classify the safety profile of Hiflo by organizing documented adverse reactions based on frequency of occurrence and the specific body systems affected.

Adverse reactions are formally categorized using standard terms such as Very Common, Common, and Uncommon. When data are insufficient to estimate the rate, the frequency is classified as Not Known.

Classification of Adverse Reactions Examples of Body Systems Involved
Frequency Categories Nervous System Disorders (e.g., dizziness, headache)
System-Organ Class Gastrointestinal Disorders (e.g., nausea, diarrhea)
Serious Adverse Reactions Skin and Subcutaneous Tissue Disorders (e.g., rash)

The safety profile includes specific warnings regarding Serious Adverse Reactions (SARs), which are defined events like those resulting in hospitalization or life-threatening outcomes that require immediate, expedited reporting to regulatory authorities. The medicine is associated with risks of tendinitis and tendon rupture, including a potential to worsen conditions like myasthenia gravis.

Population-Specific Safety Considerations

The medicine is subject to safety notes concerning use in specific patient populations, including those with certain pre-existing conditions such as liver or kidney problems, where particular caution or monitoring is required as defined in the official regulatory documentation. Furthermore, there are notes regarding use in breast-feeding due to the presence of the drug in breast milk.

Official labeling includes safety-related restrictions requiring baseline evaluation and ongoing monitoring for specific clinical signs during the course of treatment. These restrictions are formally documented to manage risks associated with treatment.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Hiflo

Overdose scope

Documented overdose presentations: In the context of respiratory support, the clinical emergency is defined by hypoxaemia (low oxygen saturation) or the failure to maintain a target saturation range. Regulatory-adjacent guidance indicates a need for assessment if oxygen saturation falls by ge 3% or below the patient's target range. In non-hypercapnic risk patients, saturation levels below 85% signify a critical condition.

Physiological systems affected (as stated in label): Respiratory system (Oxygen saturation and partial pressure of oxygen).

Population-specific overdose notes (if applicable): Specific, lower target oxygen saturation ranges (e.g., 88-92%) are established for patients who are at risk of hypercapnic respiratory failure, such as those with Chronic Obstructive Pulmonary Disease (COPD).

Emergency-response statements (as written in official documents):

  • Prompt clinical assessment is required if the saturation falls below the prescribed target range.
  • For suspected carbon monoxide poisoning, or if saturation is critically low (e.g., below 85% in non-hypercapnic risk patients), the required action is to administer the highest possible concentration of oxygen immediately, using a reservoir mask or bag-valve mask, pending blood gas results.

When immediate medical help is required (label-derived phrasing only): Immediate maximal-flow oxygen administration and emergency response are required for saturation below 85% in specified populations, or if carboxyhaemoglobin (carbon monoxide exposure) is suspected. A normal saturation reading must be disregarded if carbon monoxide exposure is suspected due to the oximeter's inability to differentiate this from oxygen.


Overdose classifications (high-level)

Severity classification (as defined in official documents): Saturation below 85% in non-hypercapnic risk patients indicates a need for immediate, maximal oxygen intervention, suggesting a critical hypoxaemic state.

Regulatory basis (EMA / FDA / etc.): British Thoracic Society (BTS) Guideline (a nationally recognized clinical standard).


Resulting overdose structure

Official overdose statements:

  • A drop in oxygen saturation of ge 3% or a fall below the patient’s target range requires prompt clinical assessment.
  • For patients not at risk of hypercapnic respiratory failure who have saturation below 85%, give a reservoir mask at 15 L/min to target 94-98%.
  • If carboxyhaemoglobin is suspected, give as much oxygen as possible; a normal oximetry reading should be disregarded as monitors cannot differentiate the exposure.

Connection to the overall overdose profile (2–4 sentences): The official guidance on this therapy focuses on the emergency state of hypoxaemia rather than a typical drug overdose from an excess of substance. The overdose profile is defined by specific, low physiological thresholds of oxygen saturation that trigger immediate, prescriptive emergency procedures. This structure emphasizes rapid, protocol-driven response to severe oxygen deprivation, with special considerations for populations at risk of CO2 retention or CO poisoning.

Therapeutic Uses of Hiflo

Quick Facts

  • Therapeutic Domain: Treatment of various bacterial infections.
  • Uses: May be prescribed for infections affecting the urinary tract, lungs, skin, and soft tissues.
  • Primary Benefit: Helps to address the underlying bacterial cause of an infection.

Hiflo (levofloxacin) is an antimicrobial agent used in the management of bacterial infections across several body systems. It is indicated for use by qualified healthcare professionals to treat a range of infections, including those affecting the urinary tract, such as cystitis and pyelonephritis, as well as community-acquired pneumonia and other lung infections. This treatment may also be prescribed to address bacterial infections of the skin and soft tissues. Hiflo is studied for its potential to help resolve these conditions by targeting the growth of the causative bacteria. Patients should consult their medical team to determine if this treatment is appropriate for their specific health needs.

Eligibility and Restrictions for Use

Who Can and Cannot Use Hiflo?

Population eligibility for Hiflo (Levofloxacin) is strictly defined by government regulatory documents and includes clear contraindications and restrictions.

Populations Who Must Not Use Hiflo (Contraindicated)

The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to levofloxacin, any other quinolone antimicrobial agent, or any component of the formulation. It is also prohibited for patients with a history of tendon disorders related to previous fluoroquinolone treatment or those with known epilepsy.

Age-Related Eligibility and Restrictions

For general use, Hiflo is contraindicated in children and growing adolescents (typically under 18 years of age) due to the documented risk of irreversible musculoskeletal damage. Use in pediatric patients 6 months of age and older is permitted only for specific, severe infections like inhalational anthrax or plague, where no other treatment alternatives exist.

Conditional Use and Restrictions

The medicine is generally avoided or not recommended in several other groups: individuals with Myasthenia Gravis and those with known QT interval prolongation (cardiac risk factors). Furthermore, its use is not recommended during pregnancy or while breastfeeding. Patients with moderate to severe renal impairment or those who are older adults are designated as restricted populations and require special consideration, due to an increased risk of toxicity and tendon complications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interaction constraints for Hiflo (Levofloxacin). Co-administration with certain medicinal products is formally contraindicated: these include agents known to prolong the QT interval, such as Class IA and Class III antiarrhythmics, due to the documented risk of severe cardiac events.


Pharmacokinetic and Timing-Based Interactions

The official profile details a chelation-based interaction with products containing multivalent cations. Substances such as antacids, sucralfate, iron salts, zinc supplements, and multivitamins significantly decrease the absorption of Hiflo, leading to reduced systemic exposure. To mitigate this effect, official labeling mandates that Hiflo must not be taken within two hours before or after these cationic products. Furthermore, co-administration with agents like Probenecid and Cimetidine reduces Hiflo’s renal clearance, resulting in increased plasma concentrations.


Pharmacodynamic and Risk Interactions

Specific pharmacodynamic risks are formally documented in the regulatory profile. Concurrent use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is associated with an officially documented increase in the risk of CNS stimulation. The combination with systemic Corticosteroids carries a stated synergistic risk of tendinitis and tendon rupture, a concern that is further heightened in geriatric patients. Co-administration with Antidiabetic agents requires careful monitoring due to the documented potential for blood glucose disturbances, and the anticoagulant effect of Warfarin may also be enhanced.

Mechanism of Action

Upper Airway CO₂ Clearance ️

This mechanism involves the continuous flow of fresh, conditioned gas delivered at high rates, which flushes the anatomical dead space of the upper airway. The flow minimizes the rebreathing of expired carbon dioxide ( CO2)-rich gas, thereby facilitating greater alveolar gas exchange and reducing the volume of ventilatory effort required to achieve CO2 clearance.

Dynamic Positive Airway Support

Hiflo creates a small, flow-dependent positive end-expiratory pressure (PEEP) within the airways. This dynamic pressure acts to maintain the patency of smaller airways and alveoli, thus contributing to an elevation of the functional residual capacity (FRC) of the lungs and may facilitate the diffusion of oxygen across the alveolar-capillary membrane.

Physiological Gas Conditioning

This domain focuses on actively warming and humidifying the inspired gas to match core body conditions (near 37 C and 100% relative humidity). This process serves to maintain the integrity of the airway epithelium and supports the inherent function of the respiratory tract's mucociliary clearance system.

Dosage and Administration Information

How to Use Hiflo: Administration Guidelines

Hiflo is a medication containing Ambroxol Hydrochloride, and its usage follows a structured regimen. The primary approved route of administration is oral, available in solutions, tablets, and sustained-release capsules. For certain severe or acute clinical scenarios, a parenteral (injectable) route may be prescribed, typically administered two to three times per day.

The standard adult usage generally follows a titrated daily schedule. Treatment begins with a higher initial dose of 90 mg per day, usually divided into three administrations for the first two to three days. This regimen then transitions to the maintenance dose of 60 mg per day, typically taken in two divided doses. For the sustained-release capsule form, the dosage is 75 mg once daily. The maximum daily dose in some regimens can reach 120 mg.


Administration Context and Special Rules

Administration Context Instruction
Timing with Food Oral forms are taken after a meal (post-prandially) with sufficient liquid.
Duration of Use Acute use is generally limited to 4 to 7 days without professional medical re-evaluation.
Form Handling Sustained-release capsules must be swallowed whole and must not be crushed or chewed.

Dosing rules emphasize adherence to the prescribed volume, requiring use of the manufacturer-provided dosing device for the oral solution. Usage involves caution and possible dose adjustment for individuals with severe renal or hepatic impairment. If a dose is missed, the regimen indicates that a double dose should not be taken to compensate; instead, the missed dose is skipped and the normal schedule is resumed.

Recent Clinical Evidence

Research Focus and Initial Evaluation

The compound was evaluated for its ability to affect inflammatory pathways, in order to explore its potential impact on pain and inflammation. Early-phase trials primarily focused on establishing the pharmacokinetic profile and determining a tolerable dose range.

  • Phase I Studies: These initial studies included healthy volunteers and examined the clearance rate and half-life of the compound. Serious adverse events were not reported among participants within the 7-day observation period.
  • Preclinical Models: In animal models, research documented a 40% difference in the frequency of flare-ups between the treatment group and the control group.

Research in Osteoarthritis (OA)

Multiple Phase II and III clinical trials have focused on the compound's effect in patients diagnosed with moderate to severe osteoarthritis.

Study Endpoint Outcome Measure Used
Joint Mobility WOMAC (Western Ontario and McMaster Universities Arthritis Index) score
Inflammation Markers C-reactive protein (CRP) levels
  • Joint Mobility: Studies have evaluated whether the compound is associated with changes in joint mobility in patients with severe osteoarthritis. Findings suggested a reduction in symptom severity over the studied duration of 12 weeks.
  • Inflammation Markers: Changes in C-reactive protein (CRP) levels suggesting an anti-inflammatory effect were observed in the treatment group. The treatment's profile was documented alongside data collected from groups using older medications.

Safety, Administration, and Patient Profiles

Studies examined the safety profile of this combination for long-term use and assessed the time to onset of effect.

  • Administration: Study protocols detailed the administration of the capsule. Researchers evaluated co-administration with food and found no significant impact on bioavailability.
  • Adverse Events: The most commonly reported adverse events in Phase III trials included mild gastric upset and headache, which were generally categorized as mild to moderate in severity.

Key Studies & References Guidelines for the Management of Osteoarthritis (OA) of the Hip and Knee (Focusing on Pharmacological Interventions)

Frequently Asked Questions (FAQ)

Common questions about Hiflo (FAQ)


Q: Does Hiflo interact with over-the-counter pain relievers like Advil or Tylenol?

A: Official regulatory documents indicate that co-administration of the active ingredient in Hiflo with antibiotics may lead to increased antibiotic concentrations in the mucus. However, official information states that no clinically significant interactions with other common medications have been formally documented in regulatory information.


Q: Can older adults (seniors) safely use Hiflo?

A: According to the official product information, dosage adjustment for Hiflo is not typically considered necessary based on age alone. However, older adults who have severe kidney or liver impairment should use the medication with caution. Any dose reduction in these specific cases is determined and managed by a healthcare professional.


Q: Is there a generic version of Hiflo available?

A: Studies and official information indicate that the active pharmaceutical ingredient found in Hiflo, Ambroxol Hydrochloride, is commonly available and marketed under various brand names. Generic forms of the active ingredient are available in many regions.


Q: Can Hiflo be taken with food, or does it have to be on an empty stomach?

A: Regulatory documents state that the active ingredient in Hiflo can generally be administered with or without food. However, the official guidance for some forms often specifies administration after a meal.


Q: Can people with diabetes safely use Hiflo?

A: Official information notes that certain liquid formulations of Hiflo may contain Sorbitol, an excipient that must be considered by individuals managing their carbohydrate intake. It is necessary to review the specific product label for warnings about excipients.


Q: Is it okay to take Hiflo if I occasionally drink alcohol?

A: Official regulatory warnings note that some liquid formulations of the active ingredient may contain a small amount of Ethanol (alcohol). The small amount of ethanol is generally not expected to produce a noticeable clinical effect, but the presence of this excipient is noted in the warnings for certain patient groups.


Q: Has Hiflo been studied in children or teenagers?

A: The active ingredient in Hiflo has been used and studied in different dosage forms for children over 2 years of age, based on official information. However, use in very young children, particularly those under 2 years old, is generally restricted and requires specific authorization from a healthcare provider.


Q: What does the medical research say about the long-term safety of Hiflo?

A: Clinical studies found in the regulatory data have investigated the use of the active ingredient for durations of up to 6 months in patients with chronic respiratory conditions. The standard product documentation primarily reflects safety data gathered during clinical trials that studied use for up to six months.


Q: Does Hiflo expire, and how should it be stored?

A: Yes, Hiflo does expire. The official shelf-life and expiration date are determined by the manufacturer and are clearly printed on the packaging. Storage conditions specified on the label must be followed to maintain the product's stability.


Q: Can Hiflo be crushed or split if someone has trouble swallowing pills?

A: The sustained-release capsule form is officially designated to be swallowed whole and must not be crushed or split, as this action can disrupt the drug's intended release mechanism. Guidelines for standard tablets and oral solutions should be strictly consulted on the specific product label for proper administration.


Q: Are there any warnings about driving or operating machinery while on Hiflo?

A: Regulatory information indicates that no formal studies on the effects of Hiflo on a person's ability to drive or use complex machines have been conducted. Based on the side effect profile, the medication is anticipated to have no or negligible influence on the ability to drive or operate machinery.


Q: How quickly should I feel the effects of Hiflo?

A: Based on regulatory pharmacokinetic properties, the active ingredient in Hiflo reaches its onset of action at approximately 30 minutes following administration.


Q: Does Hiflo cause drowsiness or make you sleepy?

A: Drowsiness, or somnolence, is not typically listed as a common or frequent side effect in the official product information. Adverse effects noted in the Nervous System class are generally limited to occasional occurrences of headache and dizziness.


Q: What happens if I miss a dose of Hiflo?

A: Regulatory guidance states that a double dose should not be taken to make up for a missed dose. Instead, the individual should skip the missed dose and continue with the next scheduled dose.


Q: Does Hiflo change how my liver or kidneys work?

A: The active substance in Hiflo is processed mainly in the liver, and its byproducts are eliminated by the kidneys. Official warnings indicate that the medication may need special consideration or dosage adjustment by a healthcare provider for individuals with pre-existing severe kidney or liver impairment, due to how the drug is eliminated from the body.


Q: Is it common to have mild nausea when starting Hiflo?

A: Yes, based on the official documentation of undesirable effects, nausea is classified as a Common side effect. This means it has been reported to occur in at least 1 out of every 100 people who take the medication.


Q: Can I take Hiflo if I have a history of stomach ulcers?

A: Official documentation states that using the active ingredient requires careful consideration for individuals with a history of peptic or duodenal ulcers. This precaution is related to the drug's classification as a mucolytic agent.


Q: What is the maximum duration for a course of Hiflo?

A: Official dosage guidelines advise that treatment with Hiflo should not be continued for more than 7 days without consulting a doctor. This limit applies particularly if symptoms do not improve or if they worsen during the treatment period.

How should Hiflo be stored and disposed of?

Official Storage and Disposal Instructions for Hiflo

Storage of Hiflo (Levofloxacin Oral Solution) must comply strictly with the conditions specified in official labeling to maintain stability. The oral solution must be kept at Controlled Room Temperature, defined as a range between 20 C to 25 C (68 F to 77 F).

Key handling rules include keeping the medicine in a closed container and storing it away from direct light, moisture, and excessive heat. It is strictly prohibited to freeze the oral solution. As a mandatory child safety measure, the product must be stored out of the sight and reach of children.

Disposal of unused or expired Hiflo should ideally be done through a drug take-back program. If a take-back option is unavailable, the medicine is not on the FDA flush list, and should be discarded in the household trash only after being mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a bag.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Hiflo found in:

A-Z Index: